Preclinical and Phase 1 clinical characterization of CI-979/ RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease
- 10 February 1995
- journal article
- clinical trial
- Published by Elsevier in Life Sciences
- Vol. 56 (11-12), 877-882
- https://doi.org/10.1016/0024-3205(95)00023-y
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study GroupPublished by American Medical Association (AMA) ,1994
- Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's diseasePublished by Elsevier ,1993
- A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study GroupJAMA, 1992
- A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's DiseaseNew England Journal of Medicine, 1992
- Coupling of ml Muscarinic Receptors to G Protein in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1991
- Cognition activatorsMedicinal Research Reviews, 1988
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalisAnnals of Neurology, 1981
- Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.BMJ, 1978
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEThe Lancet, 1976